Social Capital Suvretta Holdings Corp. III focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on searching for a target business operating in the biotechnology industry and within the organ space sub-sector. The company was incorporated in 2021 and is based in Henderson, Nevada.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - PROKIDNEY CORP. (0001850270) (Issuer)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
3 - PROKIDNEY CORP. (0001850270) (Issuer)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
424B3 - PROKIDNEY CORP. (0001850270) (Filer)
8-K - PROKIDNEY CORP. (0001850270) (Filer)
424B3 - PROKIDNEY CORP. (0001850270) (Filer)
8-K - PROKIDNEY CORP. (0001850270) (Filer)
8-K - PROKIDNEY CORP. (0001850270) (Filer)
424B3 - PROKIDNEY CORP. (0001850270) (Filer)
8-K - PROKIDNEY CORP. (0001850270) (Filer)
424B3 - PROKIDNEY CORP. (0001850270) (Filer)
8-K - PROKIDNEY CORP. (0001850270) (Filer)
10-Q - PROKIDNEY CORP. (0001850270) (Filer)
Fastest customizable press release news feed in the world
ProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol "PROK" on July 12, 2022 ProKidney receives total gross proceeds of approximately $597 million, expected to fund Phase 3 study of REACT™PIPE is led by a $125 million investment from Social Capital, with an additional $50 million from existing ProKidney investors, approximately $30 million from Suvretta Capital's Averill strategy and the remaining $370 million from institutional investors and family offices Proceeds will fund ongoing Phase 2 and 3 development program for ProKidney's lead cell therapy candidate, REACT™, accelerate manufacturing scale-out, and ultimately prepare for its global commercial launch
Social Capital Suvretta Holdings Corp. III ("SCS") today announced that it will reconvene the Extraordinary General Meeting of its shareholders to vote on the Business Combination Agreement, dated as of January 18, 2022, by and between SCS and ProKidney LP, a limited partnership organized under the laws of Ireland ("ProKidney"), acting through its general partner ProKidney GP Limited, a private limited company incorporated under the laws of Ireland, and the transactions contemplated thereby (the "Business Combination") on July 11, 2022 at 8:30 a.m., Eastern Time, physically at the offices of Wachtell, Lipton, Rosen & Katz located at 51 West 52nd Street, New York, New York 10019, and virtual
WINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of end-stage renal disease (ESRD) requiring dialysis or transplant, today published data from a patient study confirming the mechanistic action of its lead candidate REACT™ with cell marker analysis. "Renal Autologous Cell Therapy to Stabilize Function in Diabetes-Related Chronic Kidney Disease: Corroboration of Mechanistic Action with Cell Marker Analysis" by Joseph Stavas et. al. The paper, published in Kidney International Reports, describes observed improvements i
WINSTON-SALEM, N.C., June 15, 2022 (GLOBE NEWSWIRE) -- ProKidney LP ("ProKidney"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced an update on manufacturing efficiency and supply chain streamlining initiatives, which could reduce manufacturing costs. ProKidney's current costs of manufacturing REACT™ for use in its ongoing Phase 2 Clinical Trial RMCL-002 is approximately $100,000 per patient. ProKidney anticipates that these costs will be lower for its Phase 3 trials and will continue to decrease by potentially up to 50% compared to the cost of manufacturing REACT™ for its Phase 2 RMCL-002 study as it manufa
Potential for Amplified Therapeutic Effect of REACT™ with Bilateral Kidney Injections Potential to report data from enhanced delivery approach 1Q 2023 WINSTON-SALEM, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- ProKidney LP ("ProKidney"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced an update on its REGEN-007 Phase 2 clinical study of REACT™. Background - ProKidney's REGEN-002 trial is a multi-center, randomized (1-to-1) Phase 2 trial that enrolled 81 stage 3/4 CKD diabetic patients who received two injections in the same kidney six months apart. Patients are being followed for up to two years. Previously dis
WINSTON-SALEM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of both end-stage renal disease (ESRD) and the need for dialysis, today highlighted the key registrational program elements supporting development of its autologous cell therapy REACT® for diabetic CKD. The design of the Phase 3 program for REACT® is a result of our consultation with the Food & Drug Administration (FDA) for this first in class cellular therapy being developed to restore kidney function in patients with CKD. REACT® is an autologous cell therapy produced from a patie
WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and prevention of both end-stage renal disease (ESRD) and the need for dialysis, today announced the appointment of Libbie Parker McKenzie, MD, FASN as Chief Medical Officer. "On behalf of our entire team, I am excited to welcome Libbie to ProKidney. Her deep clinical, pharmacovigilance and regulatory affairs expertise will be instrumental to our continued success as we work to advance the development of our lead program, REACT®," said Tim Bertram, Ph.D., Chief Executive Officer of ProKidney. "In a
WINSTON-SALEM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney) is a leading Phase 3 clinical-stage cellular therapeutics company with Regenerative Medicine Advanced Therapy (RMAT) Designation that has the goal of delaying chronic kidney disease (CKD), preventing end-stage renal disease (ESRD), and preventing the need for dialysis. Social Capital Suvretta Holdings Corp. III (SCS) (NASDAQ:DNAC), is a special purpose acquisition company. ProKidney and SCS today announced that they will host an analyst and investor day in New York on Thursday, April 28, 2022, beginning at 8:00 a.m. ET. The analyst day will feature presentations from the ProKidney and SCS leadership teams, in
WINSTON-SALEM, N.C., April 12, 2022 (GLOBE NEWSWIRE) -- ProKidney LP ("ProKidney"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced the updated design for its REACT® Phase 3 program. REGEN-006 and REGEN-016 are expected together to enroll up to 1,200 subjects with CKD on optimized standard of care in two Phase 3 trials. Each trial is expected to enroll approximately 600 subjects with CKD due to type 2 diabetes in multiple centers in the United States, Europe, Latin America, and Asia Pacific. The FDA has indicated that these trials may be sufficient to support regulatory filing of a Biologic License Application
WINSTON-SALEM, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of end-stage renal disease (ESRD) and need for dialysis, today announced the appointment of Todd C. Girolamo as General Counsel. "We are thrilled to welcome Todd to the ProKidney team in such an important role," said Tim Bertram, Ph.D., Chief Executive Officer of ProKidney. "His experience as both an attorney and capital markets professional will be important to our future success, as we move closer to becoming a public company through our proposed merger with SCS. I look forward to wor
Live Leadership Updates
WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and prevention of both end-stage renal disease (ESRD) and the need for dialysis, today announced the appointment of Libbie Parker McKenzie, MD, FASN as Chief Medical Officer. "On behalf of our entire team, I am excited to welcome Libbie to ProKidney. Her deep clinical, pharmacovigilance and regulatory affairs expertise will be instrumental to our continued success as we work to advance the development of our lead program, REACT®," said Tim Bertram, Ph.D., Chief Executive Officer of ProKidney. "In a
WINSTON-SALEM, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of end-stage renal disease (ESRD) and need for dialysis, today announced the appointment of Todd C. Girolamo as General Counsel. "We are thrilled to welcome Todd to the ProKidney team in such an important role," said Tim Bertram, Ph.D., Chief Executive Officer of ProKidney. "His experience as both an attorney and capital markets professional will be important to our future success, as we move closer to becoming a public company through our proposed merger with SCS. I look forward to wor
Live finance-specific insights
ProKidney offers a first-of-its-kind, patented disease-modifying autologous cell therapy for treatment of chronic kidney disease ("CKD") Lead product candidate, REACT®, has potential to slow, stabilize, and even reverse decline in kidney function, delaying the onset of dialysis and potentially delivering significant cost savings to healthcare systems globally REACT® has received Regenerative Medicine Advanced Therapy ("RMAT") designation, as well as U.S. FDA and European Medicines Agency guidance, for its Phase 3 clinical program; Phase 3 trial launched in the United States on schedule in January 2022 Transaction values the combined company at an equity value of $2.64 billion post
This live feed shows all institutional transactions in real time.
SC 13G - PROKIDNEY CORP. (0001850270) (Subject)
SC 13D - PROKIDNEY CORP. (0001850270) (Subject)
SC 13D - PROKIDNEY CORP. (0001850270) (Subject)
SC 13G - PROKIDNEY CORP. (0001850270) (Subject)
SC 13G/A - PROKIDNEY CORP. (0001850270) (Subject)
SC 13D - PROKIDNEY CORP. (0001850270) (Subject)
SC 13G - Social Capital Suvretta Holdings Corp. III (0001850270) (Subject)
SC 13G/A - Social Capital Suvretta Holdings Corp. III (0001850270) (Subject)
SC 13G - Social Capital Suvretta Holdings Corp. III (0001850270) (Subject)
SC 13G - Social Capital Suvretta Holdings Corp. III (0001850270) (Subject)